Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 6/20 | 0.73 |
| ▸ | SLC22A2 | O15244 | 5/20 | 0.73 |
| ▸ | SLC22A1 | O15245 | 5/20 | 0.73 |
| ▸ | SLC22A3 | O75751 | 5/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | NOS3 | P29474 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.46 |
| ▸ | HTR3B | O95264 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 3/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7811970 | 0.85 | SLC22A2 (1.00) | PLAUSLC22A2SLC22A1SLC22A3POLB | |
| Hydrochloric Acid SCHEMBL9957964 | 0.83 | SLC22A2 (0.95) | PLAUSLC22A2SLC22A1SLC22A3POLB | |
| Nitric Acid SCHEMBL6033862 | 0.82 | CA12 (0.72) | PLAUSLC22A2SLC22A1SLC22A3POLB | |
| Bicarbonate SCHEMBL27495064 | 0.82 | SLC22A2 (0.83) | PLAUSLC22A2SLC22A1SLC22A3POLB | |
| Nitric Acid SCHEMBL6034777 | 0.81 | PLAU (0.53) | PLAUSLC22A2SLC22A1SLC22A3POLB | |
| Methylamine SCHEMBL11079804 | 0.81 | SLC22A2 (0.91) | PLAUSLC22A2SLC22A1SLC22A3POLB | |
| Nitric Acid SCHEMBL1833741 | 0.81 | PLAU (0.73) | PLAUSLC22A2SLC22A1SLC22A3POLB | |
| Nitric Acid SCHEMBL3860515 | 0.81 | PLAU (0.92) | PLAUPOLBNOS1NOS3ADRA2A | |
| Nitric Acid SCHEMBL2544085 | 0.81 | PLAU (0.73) | PLAUSLC22A2SLC22A1SLC22A3POLB | |
| Nitric Acid SCHEMBL6034160 | 0.81 | PLAU (0.47) | PLAUSLC22A2SLC22A1SLC22A3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| US-7388015-B2 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-06-17 | — | — | US | disclosed |
| EP-1572211-B1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | CYCLACEL LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7262202-B2 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| US-20070185134-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1373253-B1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | CYCLACEL LTD (GB) | 2007-06-20 | — | — | EP | disclosed |
| EP-1760082-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as anti-proliferative compounds | Cyclacel Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| EP-1430051-B1 | N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | CYCLACEL LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| EP-1187816-B1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2006-09-07 | — | — | US | disclosed |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | US | disclosed |
| EP-1430051-A1 | N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | Cyclacel Limited (GB) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004043467-A1 | ANTI-VIRAL COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| EP-1373253-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | Cyclacel Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| WO-2003029248-A1 | N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL) -N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | CYCLACEL LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
| WO-2002079193-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | CYCLACEL LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185134-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CDK2, CCNK, CDK3 | PLAU 3341/4885SLC22A2 4583/4885SLC22A1 4505/4885 |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CCNI | PLAU 3332/4885SLC22A2 4580/4885SLC22A1 4557/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | PLAU 3100/4885SLC22A2 2743/4885SLC22A1 2357/4885 |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CDK2, CCNK, CDK3 | PLAU 3341/4885SLC22A2 4583/4885SLC22A1 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.